Osiris Therapeutics is testing in new diabetics an adult stem-cell therapy that it hopes will have fewer side effects than anti-CD3 drugs.

FORBES: Magazine Article

Privately held biotech firm Tolerx, allied with GlaxoSmithkline, aims to begin, by summer, a final-stage trial of its anti-CD3 drug, otelixizumab, in 250 newly diagnosed adults.

FORBES: Delaying Diabetes

Osiris Therapeutics (nasdaq: OSIR - news - people ) is testing in new diabetics an adult stem-cell therapy that it hopes will have fewer side effects than anti-CD3 drugs.

FORBES: Delaying Diabetes

Now into this gloom comes a new type of drug, called an anti-CD3 antibody, that aims for the first time to delay or prevent development of the devastating disease by arresting the immune system's attack on pancreatic islet cells.

FORBES: Delaying Diabetes